2. Apoptosis Immunology/Inflammation
  3. Pyroptosis
  4. LDC7559

LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages .

For research use only. We do not sell to patients.

CAS No. : 2407782-01-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

LDC7559 Related Antibodies

Top Publications Citing Use of Products

    LDC7559 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 May;21(5):934-956.  [Abstract]

    LDC7559 (5 μM; 2+24 h)did not prevent cell death induced by indatraline and sertraline. U2OS cells were preincubated with a specific inhibitor for pyroptosis, LDC7559 (5 μM), for 2 h and then treated with indatraline (10 μM) or sertraline (10 μM) for 24 h.

    LDC7559 purchased from MedChemExpress. Usage Cited in: Eur J Immunol. 2025 Apr;55(4):e202350942.  [Abstract]

    LDC7559 (2 µM) and stimulated for 1 h with extracellular Ca2+ (1 mM). LDC7559 blocked inflammasome‐mediated pore formation.

    LDC7559 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2025 Mar;116(3):673-689.  [Abstract]

    LDC7559 (10 μM; L； 72 h) inhibited Mdivi‐1‐induced cell death in both BCR::ABL1‐positive and BCR::ABL1‐negative cells. Cell viabilities, live cell counts, and dead cell ratios were evaluated after 72 h of Mdivi‐1 treatment with or without inhibitors. Inhibitors used included: Caspase inhibitor Z‐VAD‐FMK (Z); gasdermin D inhibitor LDC7559 (L); necroptosis inhibitor Necrostatin‐1 (N); ferroptosis inhibitor Ferrostatin‐1.

    LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123.  [Abstract]

    LDC7559 (2.5 μM; 8 days) and disulfiram, attenuated VSMC calcification. Alizarin red staining of A7r5 cells in HP or control medium for 8 days treated with LDC7559 (2.5 μM), disulfiram (5 nM), or IL-1RA (5 μM) (scale bar 100 μm). The results were semi-quantified by the concentrations of Alizarin red.

    LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123.  [Abstract]

    LDC7559 (2.5 μM; 8 days) treatment attenuated the cleavage of GSDMD and the release of LDHA in VSMCs subjected to a phosphate burden, indicating that pyroptosis was prevented. Immunoblots of A7r5 cell lysates and supernatants after 8 days of LDC7559 treatment.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages [1].

    IC50 & Target

    Gasdermin D[1].
    In Vitro

    LDC7559 (1 and 5 μM) inhibits IL-1β release upon inflammasome activation, and significantly blocks the lethal effect of both human and murine GSDMD NT domains transfected into HEK293T cells[3].
    LDC7559 functions directly through blocking the activity of the GSDMD NT domain, rather than interfering with the activation and cleavage process[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    LDC7559 Related Antibodies
    Molecular Weight

    349.38

    Formula

    C20H19N3O3
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    COC1=C(C=CC=C1)C2=NN3C(COC(C=C(NC(C)=O)C=C4)=C4C3)=C2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (286.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.8622 mL 14.3111 mL 28.6221 mL
    5 mM 0.5724 mL 2.8622 mL 5.7244 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.51%

    SDS (251 KB)

    COA (249 KB) HNMR (279 KB) LCMS (96 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.8622 mL 14.3111 mL 28.6221 mL 71.5553 mL
    5 mM 0.5724 mL 2.8622 mL 5.7244 mL 14.3111 mL
    10 mM 0.2862 mL 1.4311 mL 2.8622 mL 7.1555 mL
    15 mM 0.1908 mL 0.9541 mL 1.9081 mL 4.7704 mL
    20 mM 0.1431 mL 0.7156 mL 1.4311 mL 3.5778 mL
    25 mM 0.1145 mL 0.5724 mL 1.1449 mL 2.8622 mL
    30 mM 0.0954 mL 0.4770 mL 0.9541 mL 2.3852 mL
    40 mM 0.0716 mL 0.3578 mL 0.7156 mL 1.7889 mL
    50 mM 0.0572 mL 0.2862 mL 0.5724 mL 1.4311 mL
    60 mM 0.0477 mL 0.2385 mL 0.4770 mL 1.1926 mL
    80 mM 0.0358 mL 0.1789 mL 0.3578 mL 0.8944 mL
    100 mM 0.0286 mL 0.1431 mL 0.2862 mL 0.7156 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    LDC7559 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    LDC75592407782-01-6LDC 7559LDC-7559PyroptosisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    LDC7559
    Cat. No.:
    HY-111674
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.